NCT00198237View on ClinicalTrials.gov

Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

December 31, 2005

Conditions
Breast Cancer
Interventions
DRUG

docetaxel & capecitabine

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Aventis Pharmaceuticals
All Listed Sponsors
collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

Indiana University School of Medicine

OTHER